Come meet Eric A. Adams, CEO of InMed Pharmaceuticals (NASDAQ: INM), a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. Specifically, InMed is developing a pipeline of rare cannabinoids across a spectrum of therapeutic applications with large unmet medical needs. Their pharmaceutical programs include a Phase 2 clinical trial, which has recently completed enrollment, studying the safety and efficacy of cannabinol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease. In addition, InMed together with it’s subsidiary BayMedica, also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

Eric Adams is a seasoned pharmaceutical executive with over 30 years of experience in capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Prior to becoming CEO of InMed, Mr. Adams previously served as CEO at enGene Inc in Vancouver and held senior positions in global market development with QLT Inc, Abbott Labratories and Fresenius AG in Germany.

Learn more about InMed’s responsibility to the safety and health of their people, the communities they call home, and the environment they operate in.

Fate Therapeutics (NASDAQ: FATE) is developing clinical-stage cellular immunotherapies for cancer and immune disorders, with an opportunity in 2018 to broadly establish the leading NK (natural killer) cell clinical franchise. The Company’s programs include:

• A first-in-class adaptive memory NK cell product candidate (FATE-NK100) designed to enhance direct tumor cell killing, resist immune checkpoints and promote endogenous T-cell anti-tumor response.

  • Investigational New Drug (IND) cleared by FDA for initiation of clinical investigation in acute myelogenous leukemia (AML)

• A next-generation mobilized peripheral blood graft (ProTmune) for the prevention of graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing transplant

  • Phase 1/2 PROTECT study ongoing

  • ProTmune granted FDA Fast Track and Orphan Drug designations

• A human induced pluripotent stem cell (iPSC) platform that enables the generation of master cell lines to renewably create off-the-shelf engineered NK- and T-cell cancer immunotherapies

  • Collaborations with University of Minnesota and Memorial Sloan Kettering for product candidate development